Waxman reiterates scientific review request

Incoming Committee on Government Reform Chair Rep. Henry Waxman (D-CA) reiterated his request that the FDA conduct a thorough scientific review of phenylephrine's effectiveness at 10 mg as used in reformulated OTC decongestants, citing a DTC ad for Schering-Plough's Claritin-D indicating the company will not reformulate it.
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.